Valuation: PREDILIFE

Market Cap 54.06L 62.6L 62.6L 50.87L 46.23L 86.95L 60Cr 88.23L 5.97Cr 2.34Cr 30Cr 2.35Cr 2.3Cr 100Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 1.02Cr 1.18Cr 1.18Cr 95.82L 87.09L 1.64Cr 112.98Cr 1.66Cr 11Cr 4.4Cr 57Cr 4.43Cr 4.33Cr 188.21Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%-3.27%+97.90%+294.86% 391.97Cr
-3.33%-12.35%+35.28%+64.10% 327.03Cr
-0.99%+8.32%+181.20%+15.82% 318.44Cr
-0.43%-2.22%+289.70%+449.11% 238.91Cr
-1.68%-5.23%-25.35%-27.61% 222.61Cr
-0.43%-3.67%+9.37% - 151.79Cr
-5.75%-6.91%+7.83%+44.98% 98Cr
+1.06%-1.20%+123.35%-43.22% 86Cr
-1.24%-2.99%-35.12%-2.85% 56Cr
Average -1.14%-2.51%+76.02%+99.40% 209.95Cr
Weighted average by Cap. -0.92%-2.55%+96.30%+139.99%

Financials

2024 2025
Net sales 5L 6L 6L 5L 4L 8L 5.47Cr 8L 54.43L 21.33L 2.74Cr 21.44L 20.97L 9.11Cr 8L 10L 10L 8L 7L 13.44L 9.27Cr 13.64L 92.24L 36.15L 4.64Cr 36.33L 35.54L 15Cr
Net income -42.65L -49.38L -49.38L -40.13L -36.47L -68.59L -47Cr -69.6L -4.71Cr -1.84Cr -24Cr -1.85Cr -1.81Cr -79Cr -39.34L -45.55L -45.55L -37.02L -33.64L -63.28L -44Cr -64.21L -4.34Cr -1.7Cr -22Cr -1.71Cr -1.67Cr -73Cr
Net Debt 35.38L 40.97L 40.97L 33.29L 30.26L 56.91L 39Cr 57.74L 3.91Cr 1.53Cr 20Cr 1.54Cr 1.5Cr 65Cr 47.78L 55.32L 55.32L 44.95L 40.86L 76.84L 53Cr 77.97L 5.27Cr 2.07Cr 27Cr 2.08Cr 2.03Cr 88Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-